Yamamura T, Da-Lin Y, Satoh J, Tabira T
Division of Demyelinating Disease and Aging, National Institute of Neuroscience, Tokyo, Japan.
J Neurol Sci. 1987 Dec;82(1-3):101-10. doi: 10.1016/0022-510x(87)90010-4.
15-Deoxyspergualin (DSG), a novel antitumor antibiotic, was tested for treatment of acute experimental allergic encephalomyelitis (EAE) in Lewis rats. Clinical and histologic signs of EAE by active sensitization with myelin basic protein were profoundly inhibited by prophylactic administration of DSG in a dose-dependent manner. By the treatment during the inductive phase, the onset of EAE was significantly delayed. Antigen-specific proliferation of lymph node cells and the ability of spleen cells to transfer EAE were suppressed but concanavalin A-induced lymphocyte proliferation was not altered. Passive EAE induced with an encephalitogenic T cell line was also prevented by DSG-treatment, although DSG did not suppress but rather augmented the activation of T cells in vitro. Taken together, DSG is not a non-specific lymphocyte toxin but a unique immunomodulator that can suppress both inductive and effector phases of EAE.
15-脱氧精胍菌素（DSG）是一种新型抗肿瘤抗生素，我们对其治疗Lewis大鼠急性实验性变应性脑脊髓炎（EAE）进行了测试。通过髓磷脂碱性蛋白主动致敏引发的EAE的临床和组织学症状，可被预防性给予DSG以剂量依赖的方式显著抑制。在诱导期进行治疗时，EAE的发病明显延迟。淋巴结细胞的抗原特异性增殖以及脾细胞转移EAE的能力受到抑制，但伴刀豆球蛋白A诱导的淋巴细胞增殖未改变。用致脑炎性T细胞系诱导的被动性EAE也可被DSG治疗所预防，尽管DSG在体外并不抑制而是增强T细胞的激活。综上所述，DSG不是一种非特异性淋巴细胞毒素，而是一种独特的免疫调节剂，可抑制EAE的诱导期和效应期。
